$10(k) Summary
Ellipse A/S Ko (4 Wy
Ellipse MultiFlex with Nd:YAG handpiece
This 5/0(k) summary is submitted in accordance with the requirements of 21 CFR Part
807.87(h) and Part 807.92.
A. Contact information and device identification:
Date of the summary: 16 May 2008 ocr 17 2008 .
Submitted by/manufacturer: Ellipse A/S
Agern Alle 11
2970 Hoersholm, Denmark
Tel: +45 4576 8808
Fax: + 45 4517 6851
Contact person: Ole Kofod
Device Trade Name: Ellipse MultiFlex (with IPL and Nd:YAG handpieces).
Device Model number: 9ESF7496 system (with 9APP7472 Laser handpiece).
Common Name: Intense Pulsed Light (IPL) & Laser.
Classification name: Laser surgical instrument for use in general and plastic surgery and in
dermatology (per 21 CFR Part 878.4810).
Device classification: Class II.
Product code: GEX
Predicate devices legally Multi-Spot Nd:YAG (K060448) manufactured by
marketed to which Ellipse  Lumenis Inc., 2400 Condensa Street, Santa Clara, CA 95051, USA.
A/S claims substantial (Laser surgical instrument for use in general and plastic surgery and
equivalence: in dermatology (per 21 CFR Part 878.4810)).
Alma Harmony long pulsed Nd: YAG (K033946) manufactured by
MSq(M2) Ltd., 7 Haeshel St., P.O.B. 3021, Caesarea Industrial park,
38900 Israel.
(Laser surgical instrument for use in general and plastic surgery and
in dermatology (per 21 CFR Part 878.4810)).
Lux1064 (K041879) manufactured by
Palomar Medical Technologies, Inc., 82 Cambridge Street,
Burlington, MA 01803, USA.
(Laser surgical instrument for use in general and plastic surgery and
in dermatology (per 21 CFR Part 878.4810)).
Ellipse Flex PPT (K052688) manufactured by
Ellipse A/S, Agern Alle 11, DK-2970 Hoersholm, Denmark, as far as
all IPL applications concerns.
(Laser surgical instrument for use in general and plastic surgery and
in dermatology (per 21 CFR Part 878.4810)).
HM WORD DOCUMENTS\102 NDYAG\FDA\SECTION $ 510(K) SUMMARY.DOC
Ole Kofod 15-05-2008. 9:21:25 Page 1 of 2

B. Description of Ellipse Multiflex:

Ellipse Multiflex is an Intense Pulsed Light (IPL) system used for long-term removal of unwanted hair; for
treatment of sun-damaged skin, including uneven pigmentation, age spots, large pores, diffuse redness, and
for the treatment of telangiectasias, port wine stains and inflammatory acne in the area of dermatology.
The system consists of a console containing power unit and control electronics with control and display
panel including software.

IPL Applicators/hand-pieces are connected to the system in order to generate light energy for treatment in
the waveband 400 nm - 950 nm.

The above was cleared under K052688.

Additionally a Nd: YAG handpiece (1064 nm) can be connected to the Ellipse MultiF lex for treatment of
vascular lesions as stated under Intended Use.

C, Intended Use:

Ellipse MultiFlex is intended for use in dermatology.

Ellipse MultiFlex used with IPL applicators (9APP7133, 7116, 7114, 7134, 7212, 7377, 7213):

e Hair removal (permanent hair reduction).

e Treatment of benign pigmented lesions (including, but not limited to solar lentigines, ephilides,
mottled pigmentation) and benign vascular lesions (including but not limited to diffuse redness,
telangiectasias, port wine stains).

e Treatment of inflammatory acne.

Ellipse MultiFlex used with Nd:YAG applicator (9APP7472):
e Treatment of leg vessels (0.1 — 3.0 mm diameter).
D. Performance Standards
The Ellipse MultiFlex Intense Pulsed Light (IPL) and Laser system has been tested according to and
complies with:

¢ US FDA 21 CFR 1040.10 and 1040.11 for class IV Laser Products.

e IEC 60601-1, UL 60601-1 and CSA C22.2 No. 601.1.

e IEC 60825-1 and IEC 60601-2-22.

e TEC 60601-1-2.

¢ Complies with the European Medical Device Directive 93/42/EEC (Annex Il).

e Manufactured under 1S013485 Quality Management System certified by DGM and QMI.

E. Substantial Equivalence conclusion:

The Ellipse MultiFlex system is substantially equivalent in terms of technological characteristics,
performance, intended use/indications for use to the predicate devices listed on page 1 of this document.
All the stated intended uses of Ellipse MultiFlex with Nd:YAG has earlier been investigated and cleared by
FDA for equipment which the performed comparison has shown to be substantially equivalent to regarding
the applications in question.

The IPL Intended Use applications, as already cleared under K052688 for Ellipse Flex PPT, is maintained
for the Ellipse MultiFlex used with IPL handpieces/applicators. The system platform remains. Ellipse
MultiF lex is the next generation of the Ellipse Flex PPT which incorporates a Nd:YAG handpiece in
addition to the IPL handpieces.

HAl WORD DOCUMENTS\102 NDY AG\FDA\SECTION 9 510(K) SUMMARY.DOC

‘Ole Kofod Thursday, 15 May 2008 Page 2 of2

- g DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
com Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850
Ellipse A/S
% Ole Kofod
Agern Allé 11 OCT 1 7 2008
DK-2970 Hersholm
Denmark
Re: K081408
Trade/Device Name: Ellipse MultiFlex
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and plastic surgery and
in dermatology
Regulatory Class: II
Product Code: GEX /
Dated: September 2, 2008
Received: September 3, 2008
Dear Ole Kofod:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class IH (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act .
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 — Ole Kofod
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Center for Devices and Radiological Health’s (CDRH’s) Office of Compliance at
(240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to
premarket notification” (21CFR Part 807.97). For questions regarding postmarket surveillance,
please contact CDRH’s Office of Surveillance and Biometric’s (OSB’s) Division of Postmarket ~
Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events
(Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems
at (240) 276-3464. You may obtain other general information on your responsibilities under the
Act from the Division of Small Manufacturers, International and Consumer Assistance
at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson

Director

Division of General, Restorative .

and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Notification
Device Name: Ellipse MultiFlex

Koy (4oY¥
Indications for Use:
Ellipse MultiFlex is intended for use in dermatology.
Ellipse MultiFlex used with IPL applicators (QAPP7133, 7116, 7114, 7134, 7212, 7377,
7213): 
e Hair removal (permanent hair reduction).

« Treatment of benign pigmented lesions (including, but not limited to solar lentigines,
ephilides, mottled pigmentation) and benign vascular lesions (including but not
limited to diffuse redness, telangiectasias, port wine stains).

« Treatment of inflammatory acne. .

Ellipse MultiFlex used with Nd:YAG applicator (QAPP7472).
e Treatment of leg vessels (0.1 — 3.0 mm diameter).
The Indications for Use for Ellipse MultiFlex are:
Application Treatment Variable
[1 [27374 [5 [6 |
Hair Removal
HR Applicator Hair (Thin, Normal, Thick) viv |wiv i
HR-S Applicator
Treatment of Benign Pigmented Lesions . . :
Same ae [Pomme venom [|e [o lo]
Tenimeteenacinis | Vestine | 7/7] |7 | 0) |
SC
emetic Panett [Pomme eevee)
Femaotaimminse [ele 9]
WA MOd Genwi,
(Signature)
(Division Sign-Off) . Ole Kofod
Division of General, Restorative, (Typed Name)
and Neurological Devices ee
(Date)
Yo¥
510(k) Number_ KOS Mo% (Premarket Notification 510(k) Number)
Prescription Use| X__ AND/OR Over-The-Counter Use
(21CER 801 Subpart D) (21 CFR 801 Subpart C)
Concurrence of CDRH, Office of Device Evaluation (ODE)

